A small Indian firm has developed some valuable new medical products using its unique biotechnology know-how. It is now trying to decide how to best serve the markets of USA, Russia and Brazil and has identified the foll

Given that investment in medicine manufacturing facilities is a major criterion for the small Indian firm, the optimal strategy would involve a differentiated approach for each market, leveraging the strengths of each entry mode while minimizing capital outlay on manufacturing facilities where possible. The overarching principle is to minimize direct investment in manufacturing facilities, especially for a small firm, while still ensuring market access and compliance. Recommended Strategy and Reasons: 1. Market USA: Strategic Alliance (Option iii) Recommendation: Enter by alliance mode with pharmaceutical firms operating in the USA, manufacturing through a 50/50 joint venture where the foreign firm takes responsibility for manufacturing. Reasons: High Regulatory Compliance: The USA has extremely stringent regulatory requirements (e.g., USFDA). A local partner with existing infrastructure and experience can navigate these complexities, significantly reducing the burden and risk for the Indian firm. Capital Investment Avoidance: The local partner taking manufacturing responsibility means the Indian firm avoids substantial capital investment in setting up facilities in the USA. Distribution and Market Access: A local partner provides immediate access to established distribution networks and market knowledge, which is crucial for medical products. Consignment Clearance: Manufacturing through a JV within the USA eliminates the complexities and delays associated with consignment-based clearance for export orders. Leveraging Partner's Capital: As a small firm, leveraging the capital investment of a foreign JV partner is highly advantageous. 2. Market Russia: Appoint Foreign Sales Agents (Option i) Recommendation: Manufacture the product in India (or a third country) and appoint local foreign sales agents to manage marketing activity in Russia. Reasons: Minimal Investment: This option requires the least capital investment in Russia, as the firm avoids setting up manufacturing or even significant marketing infrastructure. Market Challenges: Russia presents challenges like strict regulatory compliance, language barriers, a less transparent trade regime (only recently joined WTO), and the presence of oligarchs in the pharma market. Risk Mitigation: For a small firm, direct investment in such a complex and potentially less stable market carries high risk. Using sales agents allows for market penetration with lower exposure. Focus on Core Competency: The Indian firm can focus on its biotechnology know-how and manufacturing in India, while agents handle local sales. 3. Market Brazil: Wholly Owned Subsidiary (Option ii) Recommendation: Manufacture the product in Brazil and set up a wholly-owned subsidiary to manage marketing. Reasons: Growth Market: Brazil is an important and growing market for biotech products, offering significant opportunities in terms of market size and future growth. Similarities with India: Being in the Southern Hemisphere, there are similarities in disease patterns, which could be advantageous for the Indian firm's products. Lower Competition: The market may have lower competition and fewer established players, offering scope for the Indian firm to establish a strong presence. Regional Trade Bloc Access: Brazil is a member of Mercosur, providing free trade opportunities with neighboring Latin American countries, which a WOS can leverage for regional expansion. Control: A WOS offers full control over manufacturing, marketing, and intellectual property, which is valuable for unique biotechnology products. While it involves manufacturing investment, the long-term growth potential and regional access make it a worthwhile strategic investment for this specific market. The firm can potentially start with a smaller-scale manufacturing unit and expand as the market grows. Summary of Choice based on Investment Criteria: The chosen strategy minimizes direct manufacturing investment in the USA (partner manufactures) and Russia (no manufacturing investment), while strategically placing manufacturing investment in Brazil due to its high growth potential and regional hub status. This balanced approach allows the small Indian firm to enter diverse markets effectively while managing its capital resources prudently.